{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:15:43Z","timestamp":1791375343973,"version":"4.3.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cabotegravir, an integrase strand transfer inhibitor, and rilpivirine, an NNRTI, constitute the first long-acting (LA), injectable, two-drug ART regimen approved for the maintenance of virological suppression in persons living with HIV-1 (PLHIV). The aim of this study was to assess clinical effectiveness and tolerability of LA cabotegravir\/rilpivirine in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, single centre study, including all PLHIV receiving LA cabotegravir\/rilpivirine as standard-of-care in our tertiary centre even if initiated in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 2014 and 2022, 126 PLHIV initiated LA cabotegravir\/rilpivirine. All were ART-experienced, and 98.4% had a viral load (VL) of &amp;lt;50 copies\/mL before LA cabotegravir\/rilpivirine initiation. Median BMI at cabotegravir\/rilpivirine initiation was 24 IQR (23\u201328). During a median follow-up of 9 months IQR (7\u201324), 27 patients discontinued cabotegravir\/rilpivirine: 5 because of virological failure, 6 for adverse events, 11 for personal reasons unrelated to treatment tolerance and 5 for other reasons. Virological failure was not associated with a higher BMI, nor with weight gain during LA intramuscular (IM) cabotegravir\/rilpivirine treatment, inadequate cabotegravir and rilpivirine concentrations, VL blips or the use of oral lead-in (OLI) or not. No drug resistance-associated mutation emerged. Adverse events leading to treatment interruption were injection-site pain (n\u200a=\u200a3) and neuropsychological side effects (n\u200a=\u200a3). A correlation between BMI and both cabotegravir and rilpivirine concentrations at 1 month post-initiation of LA-IM cabotegravir\/rilpivirine was observed, with no impact of OLI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Data from this real-world cohort of PLHIV who received cabotegravir\/rilpivirine LA injections suggest that this regimen is effective and well tolerated. Virological failures were not associated with the acquisition of resistance mutations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkae308","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T15:56:10Z","timestamp":1725551770000},"page":"2932-2938","source":"Crossref","is-referenced-by-count":25,"title":["Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-4662","authenticated-orcid":false,"given":"Alexandra","family":"Serris","sequence":"first","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales , AP-HP, H\u00f4pital Bichat-Claude Bernard, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine Marie","family":"Ferre","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMRS 1137, IAME , F-75018 Paris ,","place":["France"]},{"name":"Service de Virologie , AP-HP, H\u00f4pital Bichat-Claude Bernard, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9017-4941","authenticated-orcid":false,"given":"Quentin","family":"Le Hingrat","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMRS 1137, IAME , F-75018 Paris ,","place":["France"]},{"name":"Service de Virologie , AP-HP, H\u00f4pital Bichat-Claude Bernard, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Bachelard","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales , AP-HP, H\u00f4pital Bichat-Claude Bernard, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMRS 1137, IAME , F-75018 Paris ,","place":["France"]},{"name":"Service de Virologie , AP-HP, H\u00f4pital Bichat-Claude Bernard, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Exarchopoulos","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales , AP-HP, H\u00f4pital Bichat-Claude Bernard, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Damond","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMRS 1137, IAME , F-75018 Paris ,","place":["France"]},{"name":"Service de Virologie , AP-HP, H\u00f4pital Bichat-Claude Bernard, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Chau","family":"Phung","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales , AP-HP, H\u00f4pital Bichat-Claude Bernard, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Landman","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales , AP-HP, H\u00f4pital Bichat-Claude Bernard, Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMRS 1137, IAME , F-75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2402-643X","authenticated-orcid":false,"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales , AP-HP, H\u00f4pital Bichat-Claude Bernard, Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMRS 1137, IAME , F-75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMRS 1137, IAME , F-75018 Paris ,","place":["France"]},{"name":"Service de Virologie , AP-HP, H\u00f4pital Bichat-Claude Bernard, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Joly","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales , AP-HP, H\u00f4pital Bichat-Claude Bernard, Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMRS 1137, IAME , F-75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-537X","authenticated-orcid":false,"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMRS 1137, IAME , F-75018 Paris ,","place":["France"]},{"name":"Service de Pharmacologie-Toxicologie, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-959X","authenticated-orcid":false,"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales , AP-HP, H\u00f4pital Bichat-Claude Bernard, Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMRS 1137, IAME , F-75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"2024110323522103900_dkae308-B1","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravirotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"2024110323522103900_dkae308-B2","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravirotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2024110323522103900_dkae308-B3","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravirotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2024110323522103900_dkae308-B4","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravirotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"2024110323522103900_dkae308-B5","author":"European Medicines Agency"},{"key":"2024110323522103900_dkae308-B6","author":"European Medicines Agency"},{"key":"2024110323522103900_dkae308-B7","doi-asserted-by":"publisher","first-page":"e0078123","DOI":"10.1128\/aac.00781-23","article-title":"Pharmacokinetics and tolerability of cabotegravirotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants","volume":"68","author":"Han","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323522103900_dkae308-B8","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1111\/bcp.15439","article-title":"Population pharmacokinetics of cabotegravirotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects","volume":"88","author":"Han","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2024110323522103900_dkae308-B9","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1093\/jac\/dkab338","article-title":"Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV","volume":"76","author":"Neyens","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024110323522103900_dkae308-B10","doi-asserted-by":"publisher","first-page":"ofad217","DOI":"10.1093\/ofid\/ofad217","article-title":"Gynoid fat distribution and adipocyte trapping may explain virological failure with intramuscular long-acting cabotegravirotegravir and rilpivirine","volume":"10","author":"de Malliard","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024110323522103900_dkae308-B11","author":"Haute Autorit\u00e9 de Sant\u00e9 (HAS), Commission de la Transparence"},{"key":"2024110323522103900_dkae308-B12","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"2024110323522103900_dkae308-B13","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S1473-3099(15)00152-8","article-title":"Cabotegravirotegravir plus rilpivirine, once a day, after induction with cabotegravirotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial","volume":"15","author":"Margolis","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2024110323522103900_dkae308-B14","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1093\/cid\/ciac631","article-title":"First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic","volume":"76","author":"Christopoulos","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024110323522103900_dkae308-B15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/hiv.13370","article-title":"Compassionate use of long-acting cabotegravirotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy","volume":"24","author":"D\u2019Amico","year":"2023","journal-title":"HIV Med"},{"issue":"10 Suppl 2","key":"2024110323522103900_dkae308-B16","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1443","article-title":"Real-world use of long-acting cabotegravirotegravir + rilpivirine in the US: effectiveness in the first year","author":"Sension","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024110323522103900_dkae308-B17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","article-title":"Long-acting injectable cabotegravirotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials","volume":"85","author":"Rizzardini","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024110323522103900_dkae308-B18","author":"Lse"},{"key":"2024110323522103900_dkae308-B19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1136\/sextrans-2020-054648","article-title":"Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries","volume":"97","author":"Akinwunmi","year":"2021","journal-title":"Sex Transm Infect"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/11\/2932\/60271961\/dkae308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/11\/2932\/60271961\/dkae308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T18:52:28Z","timestamp":1730659948000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/11\/2932\/7759339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,9,17]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae308","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,9,17]]}}}